^
    Back
    Association details:
    Biomarker:CXCR4 overexpression
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Bioengineered
    Title:

    Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC)

    Published date:
    06/28/2021
    Excerpt:
    In addition, the ccRCC cells were exposed to DDP treatment, and we surprisingly found that upregulation of CXCR4 increased DDP-resistance in ccRCC cells.
    DOI:
    10.1080/21655979.2021.1943112